- Home
- FURY vs CLYM Comparison
FURY vs CLYM Comparison
Compare FURY & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- CLYM
- Stock Information
- Founded
- FURY 2008
- CLYM 2018
- Country
- FURY Canada
- CLYM United States
- Employees
- FURY N/A
- CLYM N/A
- Industry
- FURY Precious Metals
- CLYM
- Sector
- FURY Basic Materials
- CLYM
- Exchange
- FURY Nasdaq
- CLYM NYSE
- Market Cap
- FURY 91.4M
- CLYM 86.5M
- IPO Year
- FURY N/A
- CLYM 2021
- Fundamental
- Price
- FURY $0.49
- CLYM $1.22
- Analyst Decision
- FURY Strong Buy
- CLYM Buy
- Analyst Count
- FURY 1
- CLYM 1
- Target Price
- FURY $1.20
- CLYM $10.00
- AVG Volume (30 Days)
- FURY 383.9K
- CLYM 204.9K
- Earning Date
- FURY 08-07-2025
- CLYM 08-13-2025
- Dividend Yield
- FURY N/A
- CLYM N/A
- EPS Growth
- FURY N/A
- CLYM N/A
- EPS
- FURY N/A
- CLYM N/A
- Revenue
- FURY N/A
- CLYM N/A
- Revenue This Year
- FURY N/A
- CLYM N/A
- Revenue Next Year
- FURY N/A
- CLYM N/A
- P/E Ratio
- FURY N/A
- CLYM N/A
- Revenue Growth
- FURY N/A
- CLYM N/A
- 52 Week Low
- FURY $0.35
- CLYM $1.05
- 52 Week High
- FURY $0.56
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- FURY 60.12
- CLYM N/A
- Support Level
- FURY $0.51
- CLYM N/A
- Resistance Level
- FURY $0.56
- CLYM N/A
- Average True Range (ATR)
- FURY 0.03
- CLYM 0.00
- MACD
- FURY -0.00
- CLYM 0.00
- Stochastic Oscillator
- FURY 57.47
- CLYM 0.00
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.